Tigatuzumab Biosimilar: Harnessing DR5 for Targeted Cancer Therapy Tigatuzumab is a monoclonal antibody targeting death receptor 5 (DR5), a member of the … read more 17th Dec 2025 Shanza Riaz
Alemtuzumab Biosimilar: Advancing CD52-Targeted Therapy Alemtuzumab is a monoclonal antibody targeting CD52, a glycoprotein highly expressed on … read more 17th Dec 2025
Enavatuzumab Biosimilar: Advancing TWEAKR-Targeted Therapy in Cancer Enavatuzumab is a monoclonal antibody targeting TWEAK receptor (TWEAKR, also known as F … read more 17th Dec 2025
